Characteristics of the patients in the analysis
| . | N = 111 patients . |
|---|---|
| Age, median (range) | 66 (40-84) |
| Males/females (%) | 60/40 |
| Organ involvement (%) | |
| Cardiac | 65 |
| Renal | 71 |
| Liver | 15 |
| PNS | 19 |
| Soft tissue | 21 |
| Number of involved organs, (range) | 2 (1-4) |
| NT-proBNP (pg/mL), median (range) | 2297 (17.0-121 000) |
| hsTnT (ng/L), median (range) | 42 (3-338) |
| Involved FLC (mg/L), median (range) | 235 (9-900) |
| Mayo stage (%) | |
| I | 20 |
| II | 49 |
| III | 31 |
| Stage IIIB (Mayo stage III and NTproBNP >8500 pg/mL) (%) | 19 |
| Proteinuria g/day, median (range) | 4.8 (0.5-39) |
| eGFR mL/min/1.73 m2, median (range) | 71 (8 to >150) |
| VWF U/dL, median (range) | 203.0 (20.0-1046.0) |
| IQR (range) | 127.0-235.0 |
| ADAMTS-13 ng/mL, median (range) | 1044 (770-1600) |
| . | N = 111 patients . |
|---|---|
| Age, median (range) | 66 (40-84) |
| Males/females (%) | 60/40 |
| Organ involvement (%) | |
| Cardiac | 65 |
| Renal | 71 |
| Liver | 15 |
| PNS | 19 |
| Soft tissue | 21 |
| Number of involved organs, (range) | 2 (1-4) |
| NT-proBNP (pg/mL), median (range) | 2297 (17.0-121 000) |
| hsTnT (ng/L), median (range) | 42 (3-338) |
| Involved FLC (mg/L), median (range) | 235 (9-900) |
| Mayo stage (%) | |
| I | 20 |
| II | 49 |
| III | 31 |
| Stage IIIB (Mayo stage III and NTproBNP >8500 pg/mL) (%) | 19 |
| Proteinuria g/day, median (range) | 4.8 (0.5-39) |
| eGFR mL/min/1.73 m2, median (range) | 71 (8 to >150) |
| VWF U/dL, median (range) | 203.0 (20.0-1046.0) |
| IQR (range) | 127.0-235.0 |
| ADAMTS-13 ng/mL, median (range) | 1044 (770-1600) |